Cargando…

Position Statement: Sharing of Clinical Research Data in Spinal Muscular Atrophy to Accelerate Research and Improve Outcomes for Patients

Detalles Bibliográficos
Autores principales:	Lochmüller, Hanns, Evans, David, Farwell, Wildon, Finkel, Richard, Goemans, Nathalie, de Lemus, Mencia, Matyushenko, Vitaliy, Muntoni, Francesco, Ouillade, Marie-Christine, Schwersenz, Inge, Wilson, Petra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004907/ https://www.ncbi.nlm.nih.gov/pubmed/29865093 http://dx.doi.org/10.3233/JND-180325

Ejemplares similares

SMA-EUROPE workshop report: opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe
por: Kayadjanian, Nathalie, et al.
Publicado: (2013)

Neurofilament as a potential biomarker for spinal muscular atrophy
por: Darras, Basil T., et al.
Publicado: (2019)

European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy
por: Kirschner, Janbernd, et al.
Publicado: (2020)

SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
por: Pechmann, Astrid, et al.
Publicado: (2019)

Nusinersen improves walking distance and reduces fatigue in later‐onset spinal muscular atrophy
por: Montes, Jacqueline, et al.
Publicado: (2019)

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
por: Darras, Basil T., et al.
Publicado: (2019)

Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States
por: Lally, Cathy, et al.
Publicado: (2017)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Spinal Muscular Atrophy (SMA) Subtype Concordance in Siblings: Findings From the Cure SMA Cohort
por: Jones, Cynthia C., et al.
Publicado: (2020)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Increased systemic HSP70B levels in spinal muscular atrophy infants
por: Eichelberger, Eric J., et al.
Publicado: (2021)

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
por: Landfeldt, Erik, et al.
Publicado: (2021)

Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
por: Viscidi, Emma, et al.
Publicado: (2021)

Correction to: Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls
por: Viscidi, Emma, et al.
Publicado: (2022)

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series
por: Alves, Christiano R.R., et al.
Publicado: (2021)

Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients
por: Capitanio, Daniele, et al.
Publicado: (2020)

Developmental milestones in type I spinal muscular atrophy
por: De Sanctis, Roberto, et al.
Publicado: (2016)

Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
por: Verhaart, Ingrid E. C., et al.
Publicado: (2017)

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
por: Darras, Basil T., et al.
Publicado: (2019)

Combination disease‐modifying treatment in spinal muscular atrophy: A proposed classification
por: Proud, Crystal M., et al.
Publicado: (2023)

Editorial: Spinal Muscular Atrophy: Evolutions and Revolutions of Modern Therapy
por: Finkel, Richard S., et al.
Publicado: (2020)

Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164–76. doi:10.1007/s12325-019-00923-8
por: Sandrock, Alfred W., et al.
Publicado: (2019)

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
por: Rodger, Sunil, et al.
Publicado: (2012)

Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2019)

Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model
por: MacCannell, Drew, et al.
Publicado: (2022)

Parents' dilemma: A therapeutic decision for children with spinal muscular atrophy (SMA) type 1
por: Boursange, Sophie, et al.
Publicado: (2022)

Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients
por: Regensburger, Adrian P., et al.
Publicado: (2021)

A consensus statement on spinal muscular atrophy management in Saudi Arabia in the context of COVID-19
por: Alghamdi, Fouad, et al.
Publicado: (2020)

Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy
por: Pera, Maria C., et al.
Publicado: (2017)

Prognostic Factors and Treatment‐Effect Modifiers in Spinal Muscular Atrophy
por: Baranello, Giovanni, et al.
Publicado: (2021)

Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada
por: McMillan, H.J., et al.
Publicado: (2021)

Revised Hammersmith Scale for spinal muscular atrophy: Inter and intra-rater reliability and agreement
por: Ramsey, Danielle, et al.
Publicado: (2022)

Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy
por: Meng, Jinhong, et al.
Publicado: (2016)

The altered expression of neurofilament in mouse models and patients with spinal muscular atrophy
por: Spicer, Charlotte, et al.
Publicado: (2021)

Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen
por: Weststrate, Harriet, et al.
Publicado: (2022)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
por: De Vivo, Darryl C., et al.
Publicado: (2019)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
por: Zhou, Haiyan, et al.
Publicado: (2020)

MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide
por: Reza, Mojgan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mc1op6urdonoua9lqgrs9h6jil